James Herriott, the SVP of $EXAS, sold 1,500 shares of the company on 11-04-2025 for an estimated $105,120. We received data on the trade from a recent SEC filing. This was a sale of approximately 10.6% of their shares of this class of stock. Following this trade, they now own 12,585 shares of this class of $EXAS stock.
$EXAS Insider Trading Activity
$EXAS insiders have traded $EXAS stock on the open market 7 times in the past 6 months. Of those trades, 0 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $EXAS stock by insiders over the last 6 months:
- KATHERINE S ZANOTTI has made 0 purchases and 2 sales selling 15,207 shares for an estimated $950,612.
- BRIAN BARANICK (EVP, GM, Precision Oncology) sold 2,858 shares for an estimated $200,288
- JAMES HERRIOTT (SVP, General Counsel & Sec) has made 0 purchases and 2 sales selling 3,000 shares for an estimated $195,120.
- JAMES EDWARD DOYLE has made 0 purchases and 2 sales selling 3,485 shares for an estimated $182,399.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$EXAS Hedge Fund Activity
We have seen 265 institutional investors add shares of $EXAS stock to their portfolio, and 284 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 2,700,607 shares (-42.2%) from their portfolio in Q2 2025, for an estimated $143,510,255
- T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 2,596,623 shares (-89.0%) from their portfolio in Q2 2025, for an estimated $137,984,546
- GOLDMAN SACHS GROUP INC added 1,486,137 shares (+204.1%) to their portfolio in Q2 2025, for an estimated $78,973,320
- HOLOCENE ADVISORS, LP added 1,404,086 shares (+189.5%) to their portfolio in Q2 2025, for an estimated $74,613,130
- BLACKROCK, INC. removed 1,388,121 shares (-11.6%) from their portfolio in Q2 2025, for an estimated $73,764,749
- STATE STREET CORP removed 1,234,872 shares (-18.7%) from their portfolio in Q2 2025, for an estimated $65,621,098
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,219,545 shares (-39.0%) from their portfolio in Q2 2025, for an estimated $64,806,621
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$EXAS Analyst Ratings
Wall Street analysts have issued reports on $EXAS in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- TD Cowen issued a "Buy" rating on 11/04/2025
- BTIG issued a "Buy" rating on 11/04/2025
- Baird issued a "Outperform" rating on 11/04/2025
- Piper Sandler issued a "Overweight" rating on 10/08/2025
- Evercore ISI Group issued a "Outperform" rating on 10/07/2025
- Barclays issued a "Overweight" rating on 10/02/2025
- Craig-Hallum issued a "Buy" rating on 09/11/2025
To track analyst ratings and price targets for $EXAS, check out Quiver Quantitative's $EXAS forecast page.
$EXAS Price Targets
Multiple analysts have issued price targets for $EXAS recently. We have seen 13 analysts offer price targets for $EXAS in the last 6 months, with a median target of $77.0.
Here are some recent targets:
- Brandon Couillard from Wells Fargo set a target price of $85.0 on 11/05/2025
- Bruce D. Jackson from Benchmark set a target price of $75.0 on 11/04/2025
- Catherine Schulte from Baird set a target price of $88.0 on 11/04/2025
- Luke Sergott from Barclays set a target price of $77.0 on 11/04/2025
- Dan Brennan from TD Cowen set a target price of $90.0 on 11/04/2025
- Subbu Nambi from Guggenheim set a target price of $75.0 on 11/04/2025
- Daniel Arias from Stifel set a target price of $80.0 on 11/04/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
